extended-spectrum beta-lactamase


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

extended-spectrum beta-lactamase

Third generation cephalosporinase Microbiology A beta-lactamase produced by gram-negative enteric bacteria, in particular K pneumoniae and E coli, which are resistant to third-generation cephalosporins. See Third-generation cephalosporin.

extended-spectrum beta-lactamase

Abbreviation: ESBL
Any enzyme that makes bacteria (esp. gram-negative bacteria such as the Enterobacteriaceae) resistant to the effects of broad-spectrum beta-lactam antibiotics.
See also: beta-lactamase
References in periodicals archive ?
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
Escherichia coli was considered as producer of extended-spectrum beta-lactamases if there was a difference of [greater than or equal to] 5 mm between the zone diameter of either cephalosporins and their respective cephalosporins/clavulanate disc.
The NCCLS states in M100-S13 (M7), Table 2A, that: "strains of Klebsiella spp and E coli that produce extended-spectrum beta-lactamase (ES[beta]Ls) may be clinically resistant to therapy with penicillins, cephalosporins, or aztreonam, despite apparent in vitro susceptibility to some of these agents.
Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center.
Rapid detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases in Enterobacteriaceae using ligation-mediated amplification with microarray analysis.
CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop.
A simple and reliable method to screen isolates of Escherichia coil and Klebsiella pneumoniae for the production of TEM- and SHV-derived extended-spectrum beta-lactamases.
Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat.
May 17 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that surveyed clinicians cite extended-spectrum beta-lactamase (ESBL)-producing E.
Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.

Full browser ?